ESMO 2023 | Dr. Ryan J. Sullivan: When does targeted therapy outperform immunotherapy in patients with advanced melanoma?

ESMO 2023 | Dr. Ryan J. Sullivan: When does targeted therapy outperform immunotherapy in patients with advanced melanoma?

The landscape of advanced melanoma treatment has witnessed a remarkable transformation with the introduction of targeted therapies and immunotherapies. While immunotherapy has shown great promise in various cancer types, there exist specific scenarios where targeted therapy can outshine immunotherapy. In this article, we delve into the situations where targeted therapy may be the preferred choice for advanced melanoma patients, while also examining the comparative efficacy and potential side effects of these treatment approaches.